Anaplastic Thyroid Cancer: Outcome and the Mutation/Expression Profiles of Potential Targets
详细信息 查看全文
- 作者：Hao Wu ; Yue Sun ; Huihui Ye ; Shi Yang ; Stephanie L. Lee…
- 关键词：Anaplastic thyroid cancer ; Targeted therapy ; PDL1 ; BRAF ; c ; KIT
- 刊名：Pathology & Oncology Research
- 出版年：2015
- 出版时间：July 2015
- 年：2015
- 卷：21
- 期：3
- 页码：695-701
- 全文大小：581 KB
- 参考文献：1.Carling T, Udelsma R (2008) Thyroid tumors. In: DeVita VT, Lawrence TS, Rosenberg SA (eds) Devita, Hellman & Rosenberg鈥檚 cancer [electronic resource]: principles and practice of oncology. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, pp 1663鈥?682
2.Edge SB, Byrd DR, Compton CC et al. (eds) (2010) AJCC cancer staging handbook. 7th ed. New York, NY: Springer New York
3.Sugitani I, Miyauchi A, Sugino K et al (2012) Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC research consortium of Japan cohort Study of 677 patients. World J Surg 36:1247鈥?254View Article PubMed
4.Kebebew E, Greenspan FS, Clark OH et al (2005) Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103:1330鈥?335View Article PubMed
5.Busnardo B, Daniele O, Pelizzo MR et al (2000) A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. J Endocrinol Investig 23:755鈥?61View Article
6.Pierie J-PEN, Muzikansky A, Gaz RD et al (2002) The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 9:57鈥?4View Article PubMed
7.Haigh PI, Ituarte PH, Wu HS et al (2001) Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91:2335鈥?342View Article PubMed
8.Smallridge RC (2012) Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab 97:2566鈥?572View Article PubMed Central PubMed
9.Akaishi J, Sugino K, Kitagawa W et al (2011) Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid : Off J Am Thyroid Assoc 21:1183鈥?189View Article
10.Nehs MA, Nagarkatti S, Nucera C et al (2010) Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Surgery 148:1154鈥?162, discussion 1162View Article PubMed Central PubMed
11.Gule MK, Chen Y, Sano D et al (2011) Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res 17:2281鈥?291View Article PubMed Central PubMed
12.Nobuhara Y, Onoda N, Yamashita Y et al (2005) Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer 92:1110鈥?116View Article PubMed Central PubMed
13.Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292鈥?06View Article PubMed
14.Sipos JA, Shah MH (2010) Thyroid cancer: emerging role for targeted therapies. Ther Adv Med Oncol 2:3鈥?6View Article PubMed Central PubMed
15.Antonelli A, Fallahi P, Ferrari SM et al (2012) RET TKI: potential role in thyroid cancers. Curr Oncol Rep 14:97鈥?04View Article PubMed
16.Keir ME, Butte MJ, Freeman GJ et al (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677鈥?04View Article PubMed
17.Brahmer JR, Tykodi SS, Chow LQM et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455鈥?465View Article PubMed Central PubMed
18.Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:1鈥?2View Article
19.Hong DS, Kurzrock R, Supko JG et al (2012) A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res 18:3396鈥?406View Article PubMed
20.Yang S, Farraye FA, Mack C et al (2004) BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol 28:1452鈥?459View Article PubMed
21.Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949鈥?54View Article PubMed
22.Pollock PM, Harper UL, Hansen KS et al (2003) High frequency of BRAF mutations in nevi. Nat Genet 33:19鈥?0View Article PubMed
23.Amado RG, Wolf M, Peeters M et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
24.Khambata-Ford S, Garrett CR, Meropol NJ et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230鈥?237View Article PubMed
25.Pan Q, Pao W, Ladanyi M (2005) Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn JMD 7:396鈥?03View Article
26.Pinter F, Papay J, Almasi A et al (2008) Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn JMD 10:160鈥?68View Article
27.Oh Y-H, Kim Y, Kim Y-P et al (2010) Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons. J Mol Diagn JMD 12:644鈥?52View Article
28.Gupta-Abramson V, Troxel AB, Nellore A et al (2008) Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714鈥?719View Article PubMed Central PubMed
29.Kloos RT, Ringel MD, Knopp MV et al (2009) Phase II trial of Sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675鈥?684View Article PubMed Central PubMed
30.Pennell NA, Daniels GH, Haddad RI et al. (2008) A phase II study of gefitinib in patients with advanced thyroid cancer
31.Elliott DD, Sherman SI, Busaidy NL et al (2008) Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol 39:15鈥?0View Article PubMed
32.Lee DH, Lee GK, Kong S et al (2007) Epidermal growth factor receptor status in anaplastic thyroid carcinoma. J Clin Pathol 60:881鈥?84View Article PubMed Central PubMed
33.Fisher KE, Jani JC, Fisher SB et al (2013) Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma. J Surg Res. doi:10.鈥?016/鈥媕.鈥媕ss.鈥?013.鈥?5.鈥?03
34.Schoenfeld JD, Odejide OO, Wirth LJ et al (2012) Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib 鈥?a case report. Anticancer Res 32:1743鈥?746PubMed
35.Bible KC, Suman VJ, Molina JR et al. (2010) Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
36.Bible KC, Suman VJ, Menefee ME et al (2012) A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 97:3179鈥?184View Article PubMed Central PubMed
37.Ha HT, Lee JS, Urba S et al (2010) A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid Off J Am Thyroid Assoc 20:975鈥?80View Article
38.Kimura H, Nakajima T, Takeuchi K et al (2012) ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. Lung Cancer 75:66鈥?2View Article PubMed - 作者单位：Hao Wu (1) (2)
Yue Sun (2)
Huihui Ye (3)
Shi Yang (2)
Stephanie L. Lee (4)
Antonio de las Morenas (2)
1. Department of Pathology, Texas Children鈥檚 Hospital, Baylor College of Medicine, AB190.11, 6621 Fannin Street, Houston, TX, 77030, USA
2. Department of Pathology and Laboratory Medicine, Boston University Medical Center, Boston, MA, 02118, USA
3. Department of Pathology and Laboratory Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA
4. Section of Endocrinology, Diabetes and Nutrition, Department of Medicine, Boston University Medical Center, Boston, MA, 02118, USA - 刊物主题：Cancer Research; Oncology; Pathology; Immunology; Biomedicine general;
- 出版者：Springer Netherlands
- ISSN：1532-2807
文摘